Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. - Wikidata - awgldk - TriplyDB

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

http://www.wikidata.org/entity/Q34431835

about

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives Update on biomarkers in neuromyelitis optica B Cells and Autoantibodies in Multiple Sclerosis Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort Antibody biomarkers in CNS demyelinating diseases - a long and winding road Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India.Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.MOG antibody-associated diseases MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.Serological markers associated with neuromyelitis optica spectrum disorders in South India.MOG antibody-related disorders: common features and uncommon presentations.Mimics and chameleons of optic neuritis.Investigation-Directed Approach to Inflammatory Optic Neuropathies.Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review.Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.MOG-IgG associated optic neuritis is not multiple sclerosis.Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.Defining distinct features of anti-MOG antibody associated central nervous system demyelination.MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis.Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report.

P2860

Q21146662-BDB0050E-5A2B-46B2-9B5A-57F1672C9343 Q26748229-D41CDC89-CC00-48E1-A51D-75ADEF1BDDE9 Q26767391-0BE40570-D601-406F-84D1-2E39E73D337D Q26799789-A64EA12F-166B-4E28-8CF4-BB62A817A6BD Q26801386-4BE848A9-67F5-43AE-81DE-75921317BF7E Q28256650-03E09FAA-3B80-4750-8530-E38752E73EB2 Q28262403-3087A0CE-2311-492E-ACA6-393841BBBE70 Q29036090-5F69A487-4479-488E-80DD-C0EBA0A4A542 Q30371412-DDBADBD2-F7AA-4D5A-BBA8-88DD6DC74E02 Q33645795-33729A93-7D69-4EF6-BD3D-F9B7A8C6BE91 Q33693049-B090937E-59DF-4A9E-ACB1-F14AE83EEC20 Q34486841-1B563BCA-67A2-472F-8EEB-77A17628517E Q35023345-C7269EF2-12A7-43F7-A209-9E29209F00B3 Q35208073-B301060E-319A-46C4-876E-4CCC1A417E84 Q35833865-5665F78A-2F19-4F93-B6CC-BCAAB258A89A Q35937581-07165C2D-2BD6-499C-B61A-8B8DAD79820D Q36261569-3BDB8FC1-EEA2-4BB2-B1E3-429461572E8D Q37374434-673862A9-B134-4A18-BF75-024F4FF334B0 Q37383474-5C08176F-CD3F-45D0-8FF4-EE7950D2D91A Q37484413-E1D94ACD-C73F-47FA-8CD3-ADC2E6231DCD Q38645211-77F9B883-212A-400D-B6CE-61C7F62E0701 Q38695978-1469FA35-3FF0-463E-B8BE-FC58BD7A6A76 Q38766838-1FD6C7AE-B94C-4857-AFCA-519AA95B1E95 Q38853499-9D67FE74-065C-43EB-8F8E-08B455CFB97F Q40545113-94550983-8C76-4C06-9BF3-B54B9009282C Q41106804-9DF659F5-359C-4613-82D0-DB3A49BDEB0F Q44875571-E7249BD7-4BDB-40DA-B889-BD8109915F6B Q47284937-BACF9006-AC53-4823-A406-8DF478733378 Q47373538-72EDBDF5-0724-43CE-B4C9-E86385D0C1A1 Q49336386-7C51F9DC-3C33-4286-80C2-A6D70593679A Q50263881-C2678FD2-850C-455E-9CD9-5EFE94018397 Q50900378-55AFDA83-29D5-4C1A-AEC9-A5967580CADF Q51327401-07E51683-19F0-44FB-87BA-DA7C575D754A Q52152221-A7C17B16-4406-4CD1-9496-474A81541984 Q52603606-7DC4B695-0998-49DD-AFC1-EDB8A3FC8BFA Q52648377-78B96A07-15BC-42C1-9470-EB04C256121E Q52803391-070A39AF-1712-489E-A4DB-973FB70109BA Q53249251-E9B2BC0F-CBB8-4EF0-9A96-161D90B6E89B Q53492453-62360035-5D90-46F3-BB1D-163CABB7C616 Q55054339-136D05E8-11CF-426B-B06C-7A05A914B06D

P2860

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

http://www.wikidata.org/entity/Q34431835

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@ast

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@en

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@nl

type

label

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@ast

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@en

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@nl

prefLabel

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@ast

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@en

Antibodies to myelin oligodend ...... and recurrent optic neuritis.

@nl

P1433

Q34431835-A7E88A2B-99AB-4981-BAC8-37A4C73411C2

P1476

Q34431835-ADDB79CB-78D6-4D38-BE24-2466FFAFCDA3

P2093

Q34431835-10480FE8-A6D9-4060-87BC-CE0F15E228AB

Q34431835-17149795-8E59-42CC-B3EF-44250744CC99

Q34431835-2B535B8C-D082-40CA-93CF-7DA62F38CF0C

Q34431835-43C5AFFC-878F-40E9-8F25-1117C77F4D38

Q34431835-5083F69E-EC53-4A9B-A1F4-FF2F766B57B3

Q34431835-5259AC4A-624D-4401-8177-68D53B13326E

Q34431835-5B8DCF7B-A738-427D-9CFA-ACB0740CC4A3

Q34431835-68C21A6B-353F-4521-A19D-8AA67174FBB0

Q34431835-7185D591-82A2-4AE5-816D-0DAA6F94279C

Q34431835-8644710A-B166-42B6-A204-EFB5660FD09B

P2860

Q34431835-07535FDF-95F1-4149-97A9-107FF6FFA409

Q34431835-0B34E632-3764-4FA5-931F-D5DE063E1000

Q34431835-14252CE1-0DF8-42A7-9562-609E808F95A5

Q34431835-1BEF98D8-3E1B-46E5-9763-17C87F0E3805

Q34431835-1D8CF845-9D09-425F-BD95-8F0D9EB5F991

Q34431835-1FD97720-ADF8-4F5C-84DE-FDF59156CD1B

Q34431835-2AF6659F-0371-408B-BCF8-B175D7B7FC55

Q34431835-2C375D66-5476-4962-A80B-A7FC9C2B0B5C

Q34431835-313A3C7C-EDBE-4EC5-9AB6-5D50D70405BA

Q34431835-3DCDB68A-8438-4B70-9A16-47C0E0B4C0C6

P304

Q34431835-BFB90770-FC64-4E30-BA15-1586A4CAB908

P31

Q34431835-5B50F457-49F1-4619-9B7F-0E3C6BF00F70

P356

Q34431835-820B0239-5088-43A8-9512-AE804306DE00

P433

Q34431835-F181A593-26E1-447A-8266-3757EA3B6563

P478

Q34431835-4AF9748E-D7CA-432B-8D14-BA7D9F88F5F6

P50

Q34431835-56545E64-4794-4976-B832-A6545B6E617F

Q34431835-6A8CDBBC-B8FA-42DA-86A5-97866196B31A

P577

Q34431835-9DF6A1E6-772B-480F-93B0-8BF963E11C2F

P698

Q34431835-BB150D79-12DD-44E9-8D53-37478FF8439A

P921

Q34431835-C8C76670-4CCD-410B-972A-57916FB53F7E

P932

Q34431835-EC4D935F-F0D4-455A-9796-3EEC8B7933BD

P356

NXI.0000000000000040

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

Antibodies to myelin oligodend ...... l and recurrent optic neuritis

@en

P2093

Andrew F Bleasel

http://www.w3.org/2001/XMLSchema#string

Andrew Henderson

http://www.w3.org/2001/XMLSchema#string

Con Yiannikas

http://www.w3.org/2001/XMLSchema#string

David Booth

http://www.w3.org/2001/XMLSchema#string

Fabienne Brilot

http://www.w3.org/2001/XMLSchema#string

Graeme Stewart

http://www.w3.org/2001/XMLSchema#string

John D E Parratt

http://www.w3.org/2001/XMLSchema#string

Karrnan Pathmanandavel

http://www.w3.org/2001/XMLSchema#string

Mahtab Ghadiri

http://www.w3.org/2001/XMLSchema#string

Michael Barnett

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells

Relationship between NMO-antibody and anti-MOG antibody in optic neuritis

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

The spectrum of MOG autoantibody-associated demyelinating diseases

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

The spectrum of neuromyelitis optica.

P304

e40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000040

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Sudarshini Ramanathan

P577

2014-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25364774

http://www.w3.org/2001/XMLSchema#string

P921

oligodendrocyte

P932

4215392

http://www.w3.org/2001/XMLSchema#string